CD109 is a potential target for triple-negative breast cancer
Authors:
- 23 August 2014
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (12) , 12083-12090
Abstract
The aim of this study is to explore the expression of CD109 in breast cancer stem cells and the relationship between CD109 protein and clinicopathological characteristics of breast cancer. CD44+/CD24− tumor cells (CSCs) were selected by flow cytometry. The protein expression of CD109 was analyzed by immunohistochemistry staining, and the relationship between CD109 and clinicopathological parameters of breast cancer was determined. CD109 positively regulated the proliferation of breast CSCs in vitro, and CD109 protein expression was significantly higher in triple-negative breast cancer (TNBC) compared to non-TNBC (63.78 vs. 3.71 %, P = 0.001). Moreover, CD109 protein expression was related to the histological grade of breast cancer (P = 0.015), whereas age (P = 0.731), tumor size (P = 0.995), clinical stage (P = 0.644), and lymph node metastasis (P = 0.924) were not. In the logistic regression model, histological grade (P = 0.001) and molecular type (P = 0.001) were significantly related to CD109 expression. The patients with high expression of CD109 protein had significantly poorer postoperative disease-specific survival than those with no or low expression of CD109 protein (P = 0.001). In the Cox regression, CD109 was an independent prognostic factor (P = 0.001). CD109 is highly expressed in TNBC and is a potential biomarker for the initiation, progression, and differentiation of breast cancer tumors.Keywords
This publication has 19 references indexed in Scilit:
- Breast cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and IrinotecanPLOS ONE, 2013
- Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinomaOncoTargets and Therapy, 2013
- Clinical Implications of Stem Cell Gene Oct-4 Expression in Breast CancerAnnals of Surgery, 2011
- Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expressionPathology International, 2010
- CD109 expression levels in malignant melanomaJournal of Dermatological Science, 2010
- Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109Breast Cancer Research and Treatment, 2009
- CD109 expression in basal‐like breast carcinomaPathology International, 2008
- The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer CellsNew England Journal of Medicine, 2007
- Virtual absence of turnover in cadmium metabolism: Cd109 studies in the mouseAmerican Journal of Physiology-Legacy Content, 1961